Century Therapeutics, Inc.

73 articles about Century Therapeutics, Inc.

• Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

  4/11/2024

  Century Therapeutics announced plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional autoimmune disease indications.

• Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

  4/8/2024

  Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.

• Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

  3/19/2024

  Century Therapeutics announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET.

• Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

  3/14/2024

  Century Therapeutics, Inc. today reported financial results and business highlights for the full year ended December 31, 2023.

• Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

  3/5/2024

  Century Therapeutics announced that preclinical data from the Company’s iPSC-derived cell therapy platform will be presented in six posters at the upcoming 2024 American Association for Cancer Research Annual Meeting being held April 5-10, 2024, in San Diego, CA.

• Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

  2/1/2024

  Century Therapeutics today announced that members of the management team will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Tuesday, February 8th, 2024 at 2:30 PM ET.

• Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

  12/9/2023

  Century Therapeutics announced the presentation of initial clinical data from a single-patient case study which Century believes support the potential for a multi-dosing strategy for CAR iNK enabled by Allo-Evasion™ edits at the 65th American Society of Hematology Annual Meeting and Exposition, being held December 9-12 in San Diego.

• Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

  12/6/2023

  Century Therapeutics today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1.

• Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

  12/6/2023

  Century Therapeutics today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that the Company’s Phase 1 clinical trial may proceed to assess CNTY-101.

• Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

  11/21/2023

  Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, announced that members of the management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023 at 10:00 AM ET.

• Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

  11/9/2023

  Century Therapeutics, Inc., an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, reported financial results and business highlights for the third quarter ended September 30, 2023.

• Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer

  11/9/2023

  Century Therapeutics, Inc. announced the appointment of Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer and member of the Board, effective December 4, 2023.

• Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases

  11/9/2023

  Century Therapeutics, Inc. and FUJIFILM Cellular Dynamics, Inc. announce a new worldwide license agreement and expansion of existing licenses for the development and commercialization of cell therapies derived from iPSCs for the treatment of autoimmune and inflammatory diseases, including type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis.

• Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition

  11/2/2023

  Century Therapeutics, Inc., an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immune-oncology, announced the upcoming presentation of initial data from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas.

• Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

  9/26/2023

  Century Therapeutics announced that Greg Russotti, Ph.D., Interim Chief Executive Officer, will participate in a fireside chat at the Chardan 7th Annual Genetic Medicines Conference on Tuesday, October 3, 2023 at 9:00 AM ET.

• Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

  8/9/2023

  Century Therapeutics, Inc. today reported financial results and business highlights for the second quarter ended June 30, 2023.

• Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

  5/11/2023

  Century Therapeutics, Inc., an innovative clinical-stage biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, reported financial results and business highlights for the first quarter ended March 31, 2023.

• Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

  4/17/2023

  Century Therapeutics announced that Greg Russotti, Ph.D., ad-interim Chief Executive Officer, will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit on Monday, April 24, 2023 at 10:30 AM ET.

• Century Therapeutics Announces Leadership Changes

  4/12/2023

  Century Therapeutics today announced the appointment of Greg Russotti, Ph.D., as ad-interim Chief Executive Officer, effective April 11, 2023.

• Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates

  3/16/2023

  Century Therapeutics, Inc. today reported financial results and business highlights for the full-year ended December 31, 2022.